The extra general meeting ("EGM") of Frisq Holding AB (publ) ("FRISQ" or the "Company") was held today on 22 February 2022 and the following resolutions were passed by the meeting.
Resolution on approval of the sale of all shares in the subsidiaries
The extra general meeting has today resolved to approve the sale of all shares in the company's operating subsidiaries Frisq AB, Frisq UK LTD and Frisq USA Holding Inc, conditional on the purchase price for the shares amounting to SEK 106,460,000, that the share transfer agreement must be signed no later than 23.59 CET on 28 February 2022, and that the share transfer agreement must otherwise be on customary market terms.
The Company will announce further information in the event that a share transfer agreement has been entered into or if the conditions for the approval of the extra general meeting can no longer be met.
For further details regarding the resolutions set out above refer to the complete proposals, notice and annual accounts available at the Company's website, www.frisqholding.se.
For further information:
George Thaw, CEO, FRISQ
investor@frisq.se
About FRISQ:
FRISQ is a healthtech company built on the conviction that the quality of the care you get should not be dependent on your ability to navigate a complex system and constantly evolving treatments. The software solution FRISQ Care enables the creation of personalized, digital care plans that facilitate collaboration and secure information sharing between care teams, doctors and patients through the same platform.
Since 2016, FRISQ has been listed on Nasdaq First North Stockholm under the symbol “FRISQ”. FNCA Sweden AB is FRISQ’s Certified Adviser and can be reached via the following contact information: +46 8 528 00 399, info@fnca.se
The publication is a translation of the original Swedish text. In the event of inconsistency or discrepancy between the Swedish version and this publication, the Swedish language version shall prevail.
For more information, please visit: www.frisqholding.se